Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of lapatinib and to
see how well it works in treating patients with recurrent glioblastoma multiforme.